Finance

Beta
Lists
ABOS:NASDAQ
Acumen Pharmaceuticals Inc
$2.77
+17.37%
(+0.41) 1D
$2.76
-0.36% (-0.0100)
After hours
Closed: Jun 29, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABOS...
Open
$2.38
High
$2.79
Low
$2.38
Mkt. cap
200.07M
Avg. vol.
555.25K
Volume
850.76K
52-wk high
$3.60
52-wk low
$1.10
EPS
-$1.86
Beta
0.35
Shares outstanding
72.23M
No. of employees
60
Open
$2.38
High
$2.79
Low
$2.38
Mkt. cap
200.07M
Avg. vol.
555.25K
Volume
850.76K
52-wk high
$3.60
52-wk low
$1.10
EPS
-$1.86
Beta
0.35
Shares outstanding
72.23M
No. of employees
60
News stories
From sources across the web
About Acumen Pharmaceuticals Inc
CEO-
Employees60
FoundedJan 1, 1996
HeadquartersNewton, Massachusetts, United States
SectorBiotechnology
Websiteacumenpharm.com
Analyst ratings
Based on 2 analysts giving stock ratings to ABOS in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ABOS in the last 3 months.
Highest
Current $2.77
$8.00 (+188.81%)
Average
$8.00 (+188.81%)
Lowest
$8.00 (+188.81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Zemansky
Bank of America Securities
Buy
Maintained
$8.00
+188.8%
06/11/2026
Thomas Shrader
BTIG
Buy
Maintained
$8.00
+188.8%
04/02/2026
Geoff Meacham
Citi
Buy
Maintained
$4.00
+44.4%
01/30/2026
Last report
May 12, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.33 / -$0.46
+28.26%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
37.12M
21.97M
20.53M
1.03M
Cost of revenue
37.12M
21.97M
20.53M
1.03M
Research and development expenses
-
-
-
15.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.62M
4.54M
4.67M
4.66M
Operating expense
4.62M
4.54M
4.67M
20.12M
Total operating expenses
41.75M
26.51M
25.20M
21.15M
Operating income
-41.75M
-26.51M
-25.20M
-21.15M
Other non operating income
-169.00K
-509.00K
-174.00K
417.00K
EBT including unusual items
-40.95M
-26.45M
-25.14M
-20.74M
EBT excluding unusual items
-40.95M
-26.45M
-25.14M
-20.74M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-40.95M
-26.45M
-25.14M
-20.74M
Net profit margin
-
-
-
-
Earnings per share
-0.68
-0.44
-0.41
-0.33
Interest and investment income
2.02M
1.64M
1.32M
1.06M
Interest expense
-1.05M
-1.07M
-1.09M
-1.07M
Net interest expenses
969.00K
571.00K
235.00K
-5.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.73M
-26.50M
-25.19M
-21.14M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer